ASIM AHMAD MD NPI 1447544838

NPI Details

Asim Ahmad, MD is a hematology and oncology internal medicine in Fort Worth, TX with 14 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Asim Ahmad, MD NPI is 1447544838. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF SOUTH FLORIDA COLLEGE OF MEDICINE
Graduation Year:2011

The provider's business location address is:

800 W MAGNOLIA AVE
FORT WORTH, TX
ZIP 76104-611
Phone: (817) 759-7000
Fax: (817) 759-7027

The NPI 1447544838 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram (HCPCS:Q5110)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Advance care planning, first 30 minutes (HCPCS:99497)

The enumeration date for this NPI number is 6/3/2011 and was last updated on 2/6/2025.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: